XPro1595, an investigational therapy by INmune Bio, can lower brain inflammation in people with mild to moderate…
Articles by Forest Ray PhD
Testing of a second and higher dose of ACI-35.030, a potential Alzheimer’s vaccine, is now beginning in a Phase…
Vaccines against the flu and pneumonia are associated with a lower risk of developing Alzheimer’s disease, while infections are…
AlzeCure Pharma announced positive results from its first clinical study of ACD856 for the potential treatment of Alzheimer’s…
Amylyx Pharmaceuticals announced it has completed enrollment for the Phase 2 clinical trial of AMX0035 for treating Alzheimer’s…
Experiments on the International Space Station showed gravity affects the formation of amyloids, the pathological tangles of proteins found in…
A new biosensor using neatly aligned carbon nanotubes may bring scientists one step closer to a blood test for the…
Throughout 2019, Alzheimer’s News Today delivered daily coverage of emerging research, key findings, treatment developments, and clinical trials related…
A recent Phase 1 clinical study of a potential Alzheimer’s therapy showed positive results regarding both safety and biomarkers…